Render Target: STATIC
Render Timestamp: 2024-07-26T09:39:09.764Z
1% for the planet logo
PDP - Template Name: Antibody Duet
PDP - Template ID: *******ad0fa02

PhosphoPlus® Optineurin (Ser177) Antibody Duet #63617

    Product Information

    Product Description

    PhosphoPlus® Duets from Cell Signaling Technology (CST) provide a means to assess protein activation status. Each Duet contains an activation-state and total protein antibody to your target of interest. These antibodies have been selected from CST's product offering based upon superior performance in specified applications.

    Background

    Optineurin is a signaling protein involved in maintenance of the Golgi complex, membrane trafficking, NF-κB, and interferon signaling. Mutations in the gene encoding optineurin have been associated with human diseases including glaucoma, Paget disease of bone, and amyotrophic lateral sclerosis (ALS) (1-2). Optineurin is thought to contribute to these pathologies through regulation of inflammatory signaling, autophagy, and mitophagy (1, 3). The NF-κB-activating kinase/TANK-binding kinase 1 (NAK/TBK1) phosphorylates optineurin at serine 177, regulating optineurin’s role in autophagy and mitophagy (4-6). The tumor suppressor HACE1 ubiquitylates optineurin, promoting the interaction of optineurin with the autophagy receptor p62/SQSTM1 (7).
    Phosphorylation of optineurin at serine 177 by TBK1 enhances binding to LC3 and promotes autophagic clearance (8). Additional studies also suggest that serine 177 is phosphorylated during mitosis by PLK1 (9). In addition to serine 177, TBK1 also phosphorylates optineurin at serine 473 and 513, which can enhance its binding to ubiquitin chains and promote mitophagy (5,6).

    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    PhosphoPlus is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.